HT-1080 Transfection Reagent (Fibrosarcoma Cells)

Altogen Biosystems is a recognized manufacturer and laboratory for biological laboratories. Custom research opportunities and additional preclinical items include xenografts, drug testing, 28-day generation of stably-transfected cells, liposome encapsulation and more. Dedicated to assisting laboratories with cutting-edge and excellent services, Altogen Biosystems endeavors to improve modern laboratory technologies. Visit Altogen for xenograft models and assorted products to assist in cancer studies and preclinical laboratory research.

Cancer of connective tissue can take a variety of forms, each requiring its own specific research for drug development and understanding proliferation pathways. Fibrosarcomas, which are cancers of fibrous connective tissue characterized by immature fibroblasts, affect human infants and middle-aged males. Derived in 1972, the HT-1080 cell line can be used as a testing ground for drug research and a model for fibrosarcoma research involving genetic screening. Transfection of siRNA sequences, essential for RNAi technology, can be accomplished through state-of-the-art lipid transfection reagents , ensuring that the cells give realistic responses that can inform drug development. HT-1080 cells, though susceptible to a variety of viruses, can still be useful tools for preclinical research specific to fibrosarcomas.